Iodine status of young Burkinabe children receiving small-quantity lipid-based nutrient supplements and iodised salt: a cluster-randomised trial

Sonja Y. Hess1*, Souheila Abbeddou1, Elizabeth Yakes Jimenez2, Jean-Bosco Ouédraogo3 and Kenneth H. Brown1,4
1Program in International and Community Nutrition, Department of Nutrition, University of California Davis, Davis, CA 95616, USA
2Nutrition Program, Department of Individual, Family and Community Education, University of New Mexico, Albuquerque, NM 87131, USA
3Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso 01, Burkina Faso
4Bill & Melinda Gates Foundation, Seattle, WA 98109, USA

(Submitted 13 May 2015 – Final revision received 10 August 2015 – Accepted 12 August 2015 – First published online 28 September 2015)

Abstract
The objective of the present study was to assess the impact of providing small-quantity lipid-based nutrient supplements (SQ-LNS) on the I status of young Burkinabe children. In total, thirty-four communities were assigned to intervention (IC) or non-intervention cohorts (NIC). IC children were randomly assigned to receive 20 g lipid-based nutrient supplements (LNS)/d containing 90 µg I with 0 or 10 mg Zn from 9 to 18 months of age, and NIC children received no SQ-LNS. All the children were exposed to iodised salt through the national salt iodisation programme. Spot urinary iodine (UI), thyroid-stimulating hormone (TSH) and total thyroxine (T4) in dried blood spots as well as plasma thyroglobulin (Tg) concentrations were assessed at 9 and 18 months of age among 123 IC and fifty-six NIC children. At baseline and at 18 months, UI, TSH and T4 did not differ between cohorts. Tg concentration was higher in the NIC: IC at baseline, but this difference did not persist at 18 months of age. In both cohorts combined, the geometric mean of UI was 339 ± 36 µg/l, TSH 0.8 ± 0.4 mU/l, T4 118 (95 % CI 114, 122) nmol/l and Tg 26 (95 % CI 23, 30) µg/l at 18 months of age. Marginally more children in NIC (10 %) had low T4 (<65 nmol/l) compared with the IC (1 %) (P=0.052). Salt samples (n 106) were collected from randomly selected participants and assessed by titration for I content, which was on average 37 (sd 15) ppm (range 5–86 ppm); 95 % of households had adequately iodised salt (1> 15 ppm). A reduction of SQ-LNS I content could be considered in settings with similarly successful salt iodisation programmes.

Key words: Iodine; Lipid-based nutrient supplements; Small-quantity lipid-based nutrient supplements; Food supplements; Thyroid hormones

I is essential for the human body because it is required for thyroid hormone production. Owing to its importance in thyroid metabolism, adequate I is particularly critical for normal foetal and young child growth and development. Inadequate intake of I results in a spectrum of disorders, including goitre, impaired cognitive development and congenital abnormalities, generally referred to as I-deficiency disorders(1).

The I content of food depends on the local soil content and animal feeding practices. Thus, I deficiency generally occurs in regions with low soil I content(2,3). In areas at risk of I deficiency, salt iodisation remains the key strategy to prevent and control I deficiency(3). In particular, the WHO and UNICEF recommend providing I supplements to pregnant and lactating women and I-fortified complementary foods to children aged 7–24 months when iodised salt coverage is <50 % (4). In countries with coverage of 50–90 %, efforts should be made to improve universal salt iodisation, and targeted provision of supplementary I should be considered in the meantime.

The WHO, the International Council for the Control of Iodine Deficiency Disorders and UNICEF recommend an intake of 90 µg I/d for children <60 months of age(3), whereas the US Institute of Medicine recommends 110–150 µg/d for children over 1 year of age(4). In countries at risk of I deficiency, where universal salt iodisation programmes do not achieve high coverage, other I supplementation strategies are recommended. In particular, the WHO and UNICEF recommend providing I supplements to pregnant and lactating women and I-fortified complementary foods to children aged 7–24 months when iodised salt coverage is <50 % (5). In countries with coverage of 50–90 %, efforts should be made to improve universal salt iodisation, and targeted provision of supplementary I should be considered in the meantime.

The WHO, the International Council for the Control of Iodine Deficiency Disorders and UNICEF recommend an intake of 90 µg I/d for children <60 months of age(3), whereas the US Institute of Medicine recommends 110–150 µg/d for children over 1 year of age(4).

Abbreviations: IC, intervention cohorts; LNS, lipid-based nutrient supplements; MNP, micronutrient powders; NIC, non-intervention cohorts; SQ-LNS, small-quantity lipid-based nutrient supplements; Tg, thyroglobulin; TSH, thyroid-stimulating hormone; T4, thyroxine; UI, urinary iodine.

* Corresponding author: S. Hess, fax +1 530 752 3466, email syhess@ucdavis.edu
aged between 0 and 12 months and 90 μg/d for children between 1 and 8 years of age\(^6\). Home fortification products such as micronutrient powders (MNP) and small-quantity lipid-based nutrient supplements (SQ-LNS) are alternative vehicles for providing micronutrients including I to young children. Although the current MNP recommendations by WHO do not specify the amount of I in MNP\(^7\), the Home Fortification Technical Advisory Group recommends including 90 μg/d\(^8\). For the present study, SQ-LNS for young children was designed to provide 90 μg I/20 g (493 kJ (118 kcal)) daily portion, along with additional protein, essential fatty acids and other micronutrients\(^9\). Previous studies of MNP and SQ-LNS focused on the assessment of young children's anaemia and iron status, and only a few studies investigated the impact on other micronutrients such as vitamins A and B\(_{12}\) and Zn status\(^10\)–\(^13\). To date, there is no information available on the impact of providing MNP or SQ-LNS on young children's I status.

The primary objective of the present study was to assess the impact of supplementing local complementary foods with I-fortified SQ-LNS on the I status of young Burkinabe children exposed to iodised salt. In Burkina Faso, the addition of I to salt is mandatory since 2003. The regulations require an I content of 50–80 ppm at the time of importation and >30 ppm at retail distribution sites\(^14\). At the time when the present study was planned, available data from the 2003 National Demographic and Health Survey (DHS) indicated that only 54 % of households consumed iodised salt with >15 ppm I\(^15\).

There are suggestions that Zn is important for normal thyroid hormone homeostasis\(^16\). A secondary objective of the present study was to assess the impact of Zn intake on I status by comparing groups that received SQ-LNS containing either 10 mg Zn/d or no added Zn in a population considered to be at elevated risk for Zn deficiency.

### Methods

#### Participants

The present study was part of the larger iLiNS-ZINC trial, which is described in more detail elsewhere\(^17\). In brief, the study was designed as a partially masked, placebo-controlled, cluster-randomised intervention trial conducted from April 2010 to July 2012 in rural communities of the Dandé Health District in southwestern Burkina Faso. This study was conducted according to the guidelines laid down by the Declaration of Helsinki, and all the procedures involving human subjects were approved by the Institutional Review Boards of the Centre Muraz in Bobo-Dioulasso (Burkina Faso) and the University of California Davis (USA). All the participating guardians/caregivers provided their written informed consent. The study was registered as a clinical trial with the US National Institutes of Health (www.ClinicalTrials.gov; NCT00944281).

Children were examined for eligibility based on the following inclusion criteria: 8–8–9-9 months of age, permanent residence in the area and planned availability during the study period. Children were excluded based on the following criteria: Hb levels <50 g/L, weight-for-length ≤70 % of the median of the National Center for Health Statistics (NCHS)/WHO growth reference\(^17\), presence of bipedal oedema, other severe illnesses warranting hospital referral, congenital abnormalities potentially interfering with growth, chronic medical conditions requiring frequent medical attention, known HIV infection of infant or mother, history of allergy towards peanuts, history of anaphylaxis or serious allergic reaction to any substance requiring emergency medical care and concurrent participation in any other clinical trial.

#### Sample size

The sample size estimates for the I status assessments were based on the number of children required to detect an effect size of 0.6 (with a significance level of \(P<0.05\) and power >0.80), which was considered to be of public health significance. The target sample size per intervention group for biochemical indicators of I status was \(n = 55\), which was increased to \(n = 69\) to include an assumed attrition rate of 20 %. Owing to the cluster sampling design, the estimated sample size for the non-intervention cohort (NIC) was increased to \(n = 103\) for an assumed design effect of 1.5 (including 20 % for attrition).

Salt samples were collected from a randomly selected subsample of participants. The sample size estimates were based on the number of household salt samples required for each type of intervention to detect (with a significance of \(P<0.05\) and power >0.80) effect sizes that are consistent with the magnitude of differences observed in the salt analyses conducted in northern Côte d'Ivoire\(^18\). Assuming that approximately 15–20 % of the caregivers would not provide a salt sample, the target sample size per cohort (intervention cohort (IC) v. NIC) was approximately 50.

#### Interventions

In total, thirty-four communities were stratified by a statistician at the University of California Davis using selected indicators (population size; proximity to road and Bobo-Dioulasso; and health clinic affiliation) and assigned within strata to participate in the IC (twenty-five communities) or NIC (nine communities). Within the IC, children were randomly assigned to one of four intervention groups, which received 20 g SQ-LNS daily containing different amounts of Zn from 9 to 18 months of age\(^11\). For the present I impact study, only two intervention groups and the NIC participated in the I assessment: (1) SQ-LNS without Zn and placebo tablet (LNS-Zn0), (2) SQ-LNS with 10 mg Zn and placebo tablet (LNS-Zn10) and (3) NIC. For the purpose of the primary objective of the previously reported trial of the effects of different amounts of Zn in SQ-LNS v. dispersible Zn tablets\(^11\), all the children in the intervention groups included in the present analyses also received a placebo tablet daily. Children in the intervention groups received free treatment for diarrhoea, malaria and fever, as described in more detail elsewhere\(^11\). Children in the NIC did not receive SQ-LNS, tablets or any illness treatments during the study period.

The SQ-LNS products were developed and produced for the iLiNS project by Nutriset SAS and tested for acceptability before the trial\(^19\). The caregivers were advised to feed the daily...
ration of 20 g with two separate meals. The placebo tablets were also produced by Nutriset SAS. Caregivers were advised to continue breast-feeding and to provide children with a variety of nutritious local foods.

**Data collection**

At enrolment, children’s age was confirmed from the health card, children’s length and weight were measured and family socio-economic data were recorded, as previously described. A capillary blood sample was collected for the assessment of Hb concentration (Hemocue 201; HemoCue AB) and to perform a rapid diagnostic test (RDT) for malaria parasites (SD BIOLINE Malaria Ag P.F/Pan; Standard Diagnostics Inc.). In case of anaemia (Hb < 80 g/l) and uncomplicated illnesses at time of enrolment, all the children received free treatment according to national policy. At 9 and 18 months of age, the children’s dietary practices were assessed using non-quantitative food frequency questionnaires that elicited information on food groups consumed in the previous 24 h and in the previous 7 d.

A subset of children (n = 661) from LNS-Zn0, LNS-Zn10 and NIC were randomly selected for the biochemistry subgroup and were asked to provide venous blood and spot urine samples, as described below (Fig. 1). The biochemistry subgroup included a child if she or he was (1) the first in the concession (i.e. family compound) to be enroled in the study to avoid intra-cluster bias, (2) did not participate in any other substudy and (3) was free from fever and diarrhoea symptoms for the previous 48 h according to the caregiver. Children were assigned to the biochemistry subgroup progressively until the target sample size was reached. Household salt samples were collected from randomly selected households in this subgroup. In the IC 24 % (n = 64 of 268) and in NIC 62 % (n = 64 of 103) of all biochemical participants were assigned to the salt subgroup. Selected mothers were given a small plastic bag on the day of enrolment and were asked to return with a salt sample from their home on the day of blood and urine collection; 106 salt samples were successfully collected. Venous blood was collected in evacuated, trace-element-free polyethylene tubes containing lithium heparin (Sarstedt AG & Co.), stored on ice and transported to the field laboratory, where dried blood spots (DBS) were collected on filter paper and then stored with desiccant in sealed bags. Plasma was separated from heparinised venous blood by centrifuging at 2800 rpm for 10 min. Plasma, DBS and urine samples were stored at −20°C until shipped on dry ice to the respective laboratories for analysis. Salt samples were stored in a dry room with controlled temperature until analysis.

**Laboratory analyses**

I status was assessed based on urinary iodine (UI), whole-blood thyroid-stimulating hormone (TSH) and total thyroxine (T4) and plasma thyroglobulin (Tg) concentrations. Total I content of salt samples was determined by iodometric titration at the Institut de Recherche en Sciences de la Santé in Bobo-Dioulasso. UI was assessed at the Medical Research Council in Cape Town, South Africa, using a modification of the Sandell–Kolthoff reaction. DBS were analysed for TSH and total T4 concentrations by an automated time-resolved fluoroimmunoassay (DELFIA neonatal TSH and T4 assays; PerkinElmer Life Sciences) at the Children’s Hospital in Zurich, Switzerland.

![Flow diagram of clusters and participant progression through the I impact assessment of the iLiNS-ZINC trial. * Eligibility was determined at the level of the child. † Not participating in the I impact assessment study. § Invited if free of symptomatic fever or diarrhoea for 48 h before blood draw. ¶ Number of children who successfully provided blood and/or urine samples at both time points (9 and 18 months).](https://www.cambridge.org/core/terms. Click here to download the full-sized image.)
Tg was assessed in plasma using the Immulite 1000 Immunoassay system (Siemens) at the University of California Davis. Inadequate I status was defined as UI < 100 µg/l (26). The manufacturer’s normal reference range for TSH was 0.1–3.7 mU/l and for T<sub>4</sub> 65–165 nmol/l. There is currently a recommended normal range for Tg assessed in DBS available for only school-age children (4–40 µg/l), but not for young children (25). As there are no reference values available for young children, we also explored differences between intervention groups or cohorts at 18 months of age using standardised values and based on the upper and lower 2.5th percentile of the adjusted values for baseline values of the whole sample using general linear models. This study will report on data collected from the subgroup of children who successfully provided blood and/or urine samples both at 9 and 18 months of age for the analyses of I status.

**Statistical analyses**

Statistical analyses were carried out using SAS software for Windows (9.3; SAS Institute) using mixed models to account for the random effect of the community. Descriptive statistics (mean values and standard deviations, geometric means and 95% CI and proportions) were used to assess baseline information by group and cohort, as well as to compare children included in the I add-on study with those not included.

Length-for-age Z-score and weight-for-length Z-score were calculated using the SAS macros for the WHO Child Growth Standards (27). Breast-feeding and 24 h-complementary feeding indicators were constructed according to WHO guidelines (26). Any variables not normally distributed were transformed using Box–Cox transformations to identify the optimal transformation that leads to normality. Analyses were carried out using natural logarithmically transformed TSH and Tg and with square root transformations for T4, which were back transformed for reporting descriptive results.

I status indicators (UI, T<sub>4</sub>, TSH and Tg) were compared by study group and cohort using mixed model ANCOVA for continuous outcome variables (SAS PROC MIXED procedure) and mixed models logistic regression for dichotomous variables (SAS PROC GLIMMIX procedure). Intervention group and cohort were used as the main effects, and covariates were tested individually in a binary model before including only the significant variables in the final model. Intervention group means were compared post hoc using least-square means with the Tukey–Kramer test.

**Results**

Of the 3220 children enrolled in the iLiNS-ZINC trial (Fig. 1), 661 were randomly assigned to the biochemical substudy, and 431 of those children were free of reported fever and diarrhoea 48 h before the blood collection day. In all, 66% of those children provided a urine and/or blood sample both at baseline and at the end of the study. Mean age was 9.5 (sd 0.5) months and 25% were stunted at enrolment (Table 1). There were no significant group-wise differences in baseline child characteristics and maternal education. Maternal age and BMI were significantly higher in the LNS-Zn10 group compared with mothers in the other two groups. Maternal and child characteristics also did not differ between the children who participated in the I study and the rest of the iLiNS-ZINC participants, who were not included in the I assessment, except for the prevalence of positive baseline RDT. Children in the I study had a higher prevalence of positive baseline RDT than those not included (68 v. 61%; P=0.041).

Over the course of the trial, caregivers of participants in the IC reported very high adherence (98 (sd 2)% to SQ-LNS. All the children were breast-fed at 9 months, and 96.7% of children continued to be breast-fed at 18 months of age. In contrast, at 9 months of age, only 24.4% consumed the minimum recommended number of meals on the previous day and 15.5% met the minimum food group diversity recommended by the WHO (20). Moreover, only 11.3% consumed any kind of dairy product and 22.3% consumed any animal-source food on the previous day. By 18 months of age, 60% consumed the minimum number of meals, but only 27.4% met the minimum food group diversity, 20.7% consumed at least one dairy product and 37.0% consumed at least one source of animal food during the previous 24 h.

The geometric mean UI concentration at baseline was 220 (95% CI 192, 257) µg/l in children in the IC and 276 (95% CI 192, 397) µg/l in children in the NIC (Table 2). Baseline UI concentrations did not differ between the children in the IC and NIC. For both cohorts combined, the mean UI was significantly higher at 18 months compared with 9 months of age (P<0.0001). Although the difference in UI between the IC and NIC at 18 months of age was NS, there was a significant interaction between intervention and age. In particular, UI was significantly higher at 18 months compared with 9 months of age only in the IC (P<0.05). Only 14.8% of participants had low UI concentration at baseline, which declined to 4.0% at 18 months of age. A large proportion of children had high UI, with 18.8% and 32.5% of children having UI>500 µg/l at 9 and 18 months, respectively, although there are no specific cut-offs for excessive UI levels available for this age group (Fig. 2). The baseline UI differed between the two SQ-LNS intervention groups (P=0.043), but this difference did not persist at 18 months of age.

The geometric mean of the TSH concentration was 0.8 (95% CI 0.7–0.9) mU/l both at baseline and at the end of the study. Only one child had an elevated TSH concentration at baseline, and all children had normal TSH concentrations at 18 months of age. Similarly, most children had normal T<sub>4</sub> concentrations at 9 and 18 months of age. The prevalence of hypothyroxinaemia (low T<sub>4</sub> concentration) was 3.4% at baseline with no difference between the groups. The prevalence remained low at 18 months of age, but there was a marginally significant difference between the IC and the NIC (1.6 v. 8.9%; P=0.052).

At baseline, the geometric mean of the Tg concentration was significantly higher in children in the NIC, 33.2 (95% CI 28.8, 37.9) µg/l, compared with children in the IC, 27.5 (95% CI 25.2, 29.9) µg/l (P=0.005). However, Tg concentrations were not significantly different between the cohorts or the intervention groups at 18 months of age after controlling for baseline values.
There was also no significant difference in the prevalence of low or high Tg concentrations using the cut-offs for school-age children\(^3\) using standardised values and the upper and lower 2.5th percentiles of the adjusted baseline values of the whole sample. None of these comparisons found a significant difference in adjusted Tg by cohort. However, significantly more children (5\% vs. 6\%) in the NIC had adjusted Tg below the 2.5th percentile (10-15\(\mu\)g/L) compared with children in the IC (n 1; 0.5\% vs. 1\%, P = 0.006).

Salt samples (n 106) were successfully collected and analysed from randomly selected households. The mean I content of the salt samples was 37 ppm (ranging from 5 to 86 ppm). Only 5\% of the salt samples had an I content <15 ppm and 37\% <30 ppm.

### Discussion

I deficiency was not prevalent in the study participants at 9 and 18 months of age, and the majority of households had access to adequately iodised salt. In all 63\% of the salt samples collected at the household level had an I content of >30 ppm, the level mandated in Burkina at retail distribution sites\(^1\)\(^4\), and 95\% had >15 ppm. These results are comparable with findings from the most recent 2010 DHS, which found that 96\% of Burkina households had access to salt-containing >15 ppm, and confirmed a significant increase in programmatic coverage, as only 34\% of salt samples were found to be iodised (>15 ppm) during the 2005 DHS\(^1\)\(^5\). The provision of 90\(\mu\)g I/d in SQ-LNS did not affect UI, TSH, T4 or Tg concentrations at the end of the intervention trial investigating the impact of a home fortification product on young children in the study area, either indirectly through the consumption of breast milk or directly through the consumption of salt-consuming foods. To our knowledge, this was the first intervention trial investigating the impact of a home fortification product on young children’s I status.

TSH and T4 concentrations were homoeostatically controlled\(^3\), and thus we did not expect that the provision of the additional I would affect these biomarkers in already I-sufficient populations. However, we expected that the provision of additional I
Table 2. Urinary iodine (UI), thyroid-stimulating hormone (TSH), total thyroxine (T₄) and thyroglobulin (Tg) concentrations in children at 9 and 18 months of age participating in the iLiNS-ZINC trial (Geometric means and 95 % confidence intervals; numbers and percentages)

<table>
<thead>
<tr>
<th></th>
<th>IC*</th>
<th>NIC*</th>
<th>LNS-Zn0*</th>
<th>LNS-Zn10*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean 95 % CI</td>
<td>Mean 95 % CI</td>
<td>Mean 95 % CI</td>
<td>Mean 95 % CI</td>
</tr>
<tr>
<td>P between cohorts‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UI</td>
<td>143 80</td>
<td>76 67</td>
<td>0.043</td>
<td></td>
</tr>
<tr>
<td>UI at 9 months (µg/l)</td>
<td>222 192, 257</td>
<td>276 192, 397</td>
<td>0.103</td>
<td></td>
</tr>
<tr>
<td>UI at 18 months (µg/l)</td>
<td>356 314, 404</td>
<td>310 227, 425</td>
<td>0.380</td>
<td></td>
</tr>
<tr>
<td>Low UI at 9 months (&lt;100 µg/l, n, %)</td>
<td>25 17-5</td>
<td>8 10-0</td>
<td>0.145</td>
<td></td>
</tr>
<tr>
<td>High UI at 9 months (&gt;500 µg/l, n, %)</td>
<td>27 18-9</td>
<td>15 18-8</td>
<td>0.906</td>
<td></td>
</tr>
<tr>
<td>Low UI at 18 months (&lt;100 µg/l, n, %)</td>
<td>5 3-5</td>
<td>4 5-0</td>
<td>0.993</td>
<td></td>
</tr>
<tr>
<td>High UI at 18 months (&gt;500 µg/l, n, %)</td>
<td>50 35-0</td>
<td>22 27-5</td>
<td>0.271</td>
<td></td>
</tr>
<tr>
<td>TSH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TSH at 9 months (mU/l)</td>
<td>0.8 0.7-0.9</td>
<td>0.8 0.7-1.0</td>
<td>0.394</td>
<td>0.8 0.7-0.9</td>
</tr>
<tr>
<td>Total T₄</td>
<td>123 56</td>
<td>65 58</td>
<td>0.669</td>
<td></td>
</tr>
<tr>
<td>T₄ at 9 months (nmol/l)</td>
<td>127 119, 136</td>
<td>135 125, 146</td>
<td>0.292</td>
<td>129 119, 140</td>
</tr>
<tr>
<td>Low T₄ at 9 months (&lt;65 nmol/l, n, %)</td>
<td>4 3-2</td>
<td>2 3-6</td>
<td>0.680</td>
<td></td>
</tr>
<tr>
<td>Low T₄ at 18 months (&lt;65 nmol/l, n, %)</td>
<td>2 1-6</td>
<td>5 8-9</td>
<td>0.052</td>
<td></td>
</tr>
<tr>
<td>Tg</td>
<td>154 83</td>
<td>81 73</td>
<td>0.464</td>
<td></td>
</tr>
<tr>
<td>Tg at 9 months (µg/l)</td>
<td>27.5 25.2, 29.9</td>
<td>33.2 28.8, 37.9</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>Low Tg at 9 months (Tg &gt;4 µg/l)</td>
<td>0 0</td>
<td>0 0</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>High Tg at 9 months (Tg &gt;40 µg/l, n, %)</td>
<td>28 18-2</td>
<td>29 34-9</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>Low Tg at 18 months (Tg &lt;4 µg/l, n, %)</td>
<td>0 0</td>
<td>2 2-4</td>
<td>0.979</td>
<td></td>
</tr>
<tr>
<td>High Tg at 18 months (Tg &gt;40 µg/l, n, %)</td>
<td>29 18-8</td>
<td>17 20-5</td>
<td>0.323</td>
<td></td>
</tr>
</tbody>
</table>

IC, intervention cohort; LNS, lipid-based nutrient supplements; NIC, non-intervention cohort; SQ-LNS, small-quantity lipid-based nutrient supplements.

* Communities were cluster randomised to IC and NIC. Within the IC, children were randomly assigned to receive 20 g LNS/d containing 90 µg I with 0 mg Zn (LNS-Zn0) or 10 mg Zn (LNS-Zn10) from 9–18 months, and NIC children received no SQ-LNS. All the children received iodised salt through the national salt iodization programme.

† Adjusting for cluster randomisation (village) and age during the visit and for baseline value additionally for analysis at 18 months of age.
via SQ-LNS would have increased UI concentration. Possible explanations for the lack of the observed increase in UI are (1) less than reported adherence to SQ-LNS, (2) instability of I in SQ-LNS and/or (3) storage of excess I in the thyroid gland. The present study included a variety of methods to assess adherence\(^{21}\). Although caregivers’ reports of adherence (97 (SD 6) %) and disappearance rate of returned empty packages (98 (SD 4) %) implied very high adherence in the present study, 12 h home observations during home visits found that only 59 % of the children were offered SQ-LNS during the hours of observation\(^{21}\). Moreover, during interviews assessing knowledge, attitude and practices related to SQ-LNS at 15 months of age, half of the caregivers reported sharing of SQ-LNS during the previous week, mostly with other siblings. Thus, it is likely that the additional I intake from SQ-LNS was < 90 µg/l, which would likely also be the case in any programme setting. Although adequate amounts of I in SQ-LNS were confirmed at the time of production, and products were tested for long-term stability, it cannot be ruled out that there was some loss of I from SQ-LNS over time due to oxidation. The 1 content of the thyroid gland is 0-1 mg at birth and increases to 8-15 mg by adulthood; therefore, it is also possible that some of the additionally provided I was taken up by the thyroid gland and stored rather than excreted.

Dietary I intake was not assessed in our study population. However, based on non-quantitative food frequency questionnaires, children’s diets were primarily based on cereal, with poor reported dietary diversity and intake of animal-source foods, including dairy, at 9 and 18 months of age\(^{20}\). Based on this presumed inadequate dietary intake, it can be assumed that the I intake from foods containing iodised salt was limited, particularly at 9 months of age. In contrast, considering that all the children were breast-fed at 9 months and almost all children continued to be breast-fed at 18 months of age, it is likely that most children benefitted from the salt iodisation programme indirectly via breast milk. The 1 content of breast milk varies widely and depends on the maternal I status\(^{29}\).

The tolerable upper intake level (UL), the highest average daily I intake that is likely not to pose adverse health risks, is set at 200 µg I/d for children aged between 1 and 3 years\(^{6,30}\). Assuming a breast milk consumption of 620 and 550 g/d at 9 and 18 months, respectively\(^{31}\), and a median breast milk I content of 146 µg/l as found in a study in the USA among women with adequate I intake\(^{32}\), the frequently breast-fed iLNS-ZINC study participants consumed approximately 80-90 µg I/d through breast milk. Little is known about salt intake among young African children, but assuming a salt intake of 2 g/d\(^{33}\) and considering the median I content of salt of 37 ppm, I intake from salt would be approximately 74 µg/d. Thus, based on these estimates, children in this setting may already consume more than the UL even without considering the I provided in SQ-LNS. At present, no cut-off of UI has been established to identify young children with excessive I intakes and the normal range for Tg has not been determined for early childhood\(^{5,26}\). All children in the study population had normal TSH concentrations and most had T\(_4\) concentrations within the normal range, implying normal thyroid function. This leads us to the conclusion that, although providing 90 µg additional I/d in SQ-LNS may have been more than necessary, it does not seem to have adversely affected thyroid metabolism at 18 months of age.

This is the first randomised clinical trial assessing the impact of providing Zn on I status. The addition of 10 mg Zn to a daily ration of SQ-LNS did not have an impact on any of the measured indicators of I status and thyroid metabolism. To date, the evidence of interactions between I and Zn metabolism is inconclusive and is mostly based on cross-sectional studies in humans\(^{16}\). One Zn-depletion study in six young men found

![Fig. 2. Distribution of urinary iodine (UI) concentration at 9 and 18 months of age.](image-url)
that serum TSH, total T4 and free T4 concentrations tended to decrease during the period of low Zn intake (5-5 mg/d for 54 d), but only free T4 was significantly reduced (34). It is possible that Zn deficiency was not severe enough in the study population to have affected thyroid metabolism. Zn deficiency was common and 35 and 54% of children at 9 and 18 months, respectively, had low plasma Zn concentrations (<650 µg/l) (11). However, the intervention also had no effect on plasma Zn concentration, possibly indicating inadequate adherence to the study supplements or poor Zn absorption.

Strengths of this study include the high participation rates and continuous training and rigorous supervision of field staff. In addition, I status was assessed using a variety of recommended biochemical indicators in urine and blood, the salt iodisation programme was assessed by titration of salt samples collected from participating families and multiple strategies were used to assess adherence to SQ-LNS (21). Thus, the present study provided a broad overview of I and thyroid status, as well as potential dietary sources of I. The target sample size was calculated based on an effect size of 0.6 and a three-group comparison (with a significance level of P<0.05 and power>0.80). However, considering the study objectives, we decided that two-group comparisons (IC v. NIC; LNS-Zn10 v. LNS-Zn10) would be more appropriate. Post hoc power calculations show that we were powered to detect an effect size of 0.54 and 0.55 for Tg and UI concentrations, respectively, and 0.67 for TSH and T4 concentrations for the comparison between the IC and the NIC. Thus, our sample was less adequate for comparing TSH and T4 concentrations than originally planned. However, as the mean concentrations of these indicators were so similar, it is unlikely that a larger sample size would have influenced our conclusions.

In conclusion, in settings with high coverage of universal salt iodisation and continued breast-feeding, a reduction in the I content added to home fortification products such as SQ-LNS should be considered. Before including I in home fortification products in countries with established salt iodisation programmes, salt samples should be tested at the household level for adequate I content, and ideally I status of the target population should be assessed. However, further assessments are needed in other countries, particularly in countries where the universal salt iodisation programme is less well established.

Acknowledgements

The authors thank the entire iLiNS-ZINC study staff. Special thanks go to Jérôme W. Somé, Zinéwindé P. Ouédraogo, Faustin Ye, Jean-Fidele Bationo and Lucien Bado (Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso) for their support during data collection and salt analyses, Emmerentia Strydom (Medical Research Council, Cape Town, South Africa) for UI analyses, Janet Peerson (University of California Davis, USA) for assistance with the statistical analyses and the iLiNS Project Steering Committee (www.ilins.org) for technical support. Finally, the authors sincerely appreciate the support of the participating children and their parents, the local communities and the staff of the Health District of Dandé.

The project was funded by a grant from the Bill & Melinda Gates Foundation to the University of California, Davis (K. G. Dewey, grant no. 49817) and by Sight and Life (S. Y. H., grant no. 20010008). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation or Sight and Life. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

K. H. B., S. Y. H. and J. B. O. were responsible for the iLiNS-ZINC study design, S. Y. H. designed the I add-on study, S. A. and E. Y. J. implemented the research and S. Y. H., K. H. B., and J. B. O. supervised data collection. S. A. completed the statistical analyses and S. Y. H. drafted the manuscript. All authors read and approved the final version of the manuscript.

K. H. B. has worked as a consultant and later as an employee for the Bill & Melinda Gates Foundation. None of the other authors has any conflicts of interest to declare.

References


